Figueroa Barrios R R
Medicina UNMSM, Perú.
Rev Gastroenterol Peru. 1996 Sep-Dec;16(3):228-43.
Great advances has been achieved in the last 10 years in the study of acute and chronic viral hepatitis. The enigma of non-A non-B viral hepatitis was disclosed when C virus was identified and later when E virus was isolated. New viruses has been searched to explain non-A to non-E viral hepatitis, being reported recently G virus. Epidemiology and clinical aspects has been reviewed identifying unusual clinical forms: choletasic and relapsing hepatitis in HAV infection; escape mutants B virus hepatitis in HVB infection; and the silent evolution to chronicity in more than 70% of cases in HVC infection. Diagnostic techniques has been developed to asses serum antibodies and the virus itself. It is important to quantitate the viral particles in the serum before treatment. PCR technique has been used with good results. A and E virus do not remain in the host and permanent inmunity is obtained after infection is resolved. 10% of B and 80% of C viral hepatitis goes to chronicity. So far, the only drug used to treat chronic viral B, D and C hepatitis is interferon alfa, obtaining good response en 40%. Combinations with Rivabirin and increasing the dose, frequency and duration of interferon treatment are in study. lt is a recomendation to treat acute HCV infection with Interferon alfa to prevent chronicity. Vaccines against A and B virus are used, being included in childhood vaccination programs. No HVC vaccine has developed probably to constant virus mutancy. New chalenges are present in this field and in the identification of new hepatitis viruses.
在过去10年里,急性和慢性病毒性肝炎的研究取得了巨大进展。当丙型肝炎病毒被识别以及后来戊型肝炎病毒被分离出来时,非甲非乙型病毒性肝炎的谜团得以揭开。人们一直在寻找新的病毒来解释非甲至非戊型病毒性肝炎,最近报道了庚型肝炎病毒。对流行病学和临床方面进行了综述,发现了一些不寻常的临床形式:甲型肝炎病毒感染中的胆汁淤积性和复发性肝炎;乙型肝炎病毒感染中的乙型肝炎病毒逃逸突变体;丙型肝炎病毒感染中超过70%的病例会悄然发展为慢性。已经开发出诊断技术来评估血清抗体和病毒本身。在治疗前对血清中的病毒颗粒进行定量很重要。聚合酶链反应技术已被使用并取得了良好效果。甲型和戊型肝炎病毒不会在宿主体内留存,感染消除后可获得持久免疫力。10%的乙型和80%的丙型病毒性肝炎会发展为慢性。到目前为止,用于治疗慢性乙型、丁型和丙型病毒性肝炎的唯一药物是α干扰素,40%的患者有良好反应。与利巴韦林联合使用以及增加干扰素治疗的剂量、频率和持续时间正在研究中。建议用α干扰素治疗急性丙型肝炎病毒感染以预防慢性化。已使用甲型和乙型肝炎病毒疫苗,并将其纳入儿童疫苗接种计划。可能由于病毒不断变异,尚未研发出丙型肝炎病毒疫苗。该领域以及新肝炎病毒的识别存在新的挑战。